-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UZDjRaMvrKD5PKe5qG9QVE9fcy3s5hqSsIeoDWrRYtiip3HyUnS5SFosxGJ6idp1
 0l1bF38vS5PItWesH9ZKLg==

<SEC-DOCUMENT>0001193125-07-134941.txt : 20070613
<SEC-HEADER>0001193125-07-134941.hdr.sgml : 20070613
<ACCEPTANCE-DATETIME>20070613170401
ACCESSION NUMBER:		0001193125-07-134941
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20070613
DATE AS OF CHANGE:		20070613
EFFECTIVENESS DATE:		20070613

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRYO CELL INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000862692
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-SERVICES, NEC [8900]
		IRS NUMBER:				223023093
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23386
		FILM NUMBER:		07917955

	BUSINESS ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
		BUSINESS PHONE:		7277230333

	MAIL ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG. B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ddefa14a.htm
<DESCRIPTION>PROXY
<TEXT>
<HTML><HEAD>
<TITLE>Proxy</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="4"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SCHEDULE 14A </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>(RULE 14A-101)
</B></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Proxy Statement Pursuant to Section 14(a) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Filed by the Registrant: <FONT FACE="WINGDINGS">&#120;</FONT>
&nbsp;&nbsp;Filed by a Party other than the Registrant: </FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Preliminary Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B> </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Definitive Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Definitive Additional Materials </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12 </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CRYO-CELL INTERNATIONAL, INC. </B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"
ALIGN="left"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Payment of Filing Fee (Check the appropriate
box): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">No fee required. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Title of each class of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Aggregate number of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was
determined): </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Proposed maximum aggregate value of transaction: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(5)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Total fee paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fee paid previously with preliminary materials. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the form or schedule and the date of its filing. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amount previously paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form, schedule or registration statement no.: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Filing party: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date filed: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g73952img001.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>June&nbsp;13, 2007 </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>VOTE THE WHITE CARD FOR STRONG MANAGEMENT AND </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SUSTAINABLE LONG-TERM PERFORMANCE </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Dear Fellow Shareholder: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman"
SIZE="2">Cryo-Cell&#146;s Annual Shareholder Meeting will be held on July&nbsp;16</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"> in Oldsmar, Florida. This year
your vote for the Company&#146;s Board nominees is more critical than ever before. That&#146;s why we are asking for just a few minutes of your time to consider your Board&#146;s accomplishments and objectives and to vote your shares. Simply put,
your Company&#146;s future is at stake. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Whether or not you plan to attend the Annual Meeting, your Board of Directors urges you to vote FOR your
Board&#146;s nominees by signing, dating and returning the enclosed WHITE PROXY CARD today. </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>YOUR BOARD HAS A PROVEN TRACK RECORD OF
PERFORMANCE AND A SOLID </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>STRATEGIC PLAN TO ACHIEVE GLOBAL LEADERSHIP IN STEM CELL INNOVATION </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In fiscal year 2003, which began before your current Board and management was in place; the Company had $7.55 million in revenue and $7.5 million in net losses.
Approximately a year and a half after current management was in place, revenue for fiscal year 2005 almost doubled to $14.5 million and the Company registered $1 million in net income. <I><U>The Company delivered nine consecutive quarters of
profitability from the first quarter of 2004 through the first quarter of 2006.</U></I> Consolidated revenues in fiscal year 2006 increased approximately 19% from fiscal year 2005 to $17.2 million. In Cryo-Cell&#146;s most recently reported Q107,
revenues increased by 13% over Q106. <I>In other words, your Company has made continuing progress quarter over quarter; year over year.</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In early 2006,
the Cryo-Cell Board of Directors made the carefully evaluated decision to take a bold strategic step forward by investing in the growth of our business as part of our long-term strategic plan, with keen focus on repositioning the U-Cord<FONT
FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>&reg;<FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT> service, expanding our market reach and achieving
product diversification. We continue to believe that this chosen strategy will serve as the optimal pathway to create long-term and sustainable value for Cryo-Cell shareholders over time. Highlights of our progress include: </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The May 2007 announcement of Cryo-Cell&#146;s successful isolation of the maternal placental stem cell (MPSC) with new therapeutic potential for advancing
women&#146;s healthcare. Cryo-Cell has filed patent applications on its proprietary technology and is preparing to commercialize its technology into an exclusive new service offering involving the collection and preservation of maternal stem cells
from placenta at the time of birth. The Company is partnering with several prominent academic institutions specializing in regenerative medicine and has commenced preclinical (animal) studies as part of Cryo-Cell&#146;s MPSC commercialization
strategy. </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The successful 2006 implementation of comprehensive strategic initiatives designed to reposition and re-brand Cryo-Cell&#146;s signature U-Cord<FONT
FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>&reg;<FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT> product with innovative industry-exclusive and
competitively differentiated service enhancements. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">We believe that we are the only private family cord blood bank with current Good Manufacturing Practice/Good Tissue Practice (cGMP/cGTP) compliance; International
Organization for Standardization (ISO) and AABB (formerly American Association of Blood Banks) accreditation. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Our outstanding client satisfaction ratings for 2006 with nearly 40% of Cryo-Cell clients rating our service as &#147;far exceeds expectations&#148; as measured in
an independent survey conducted by Sterling Research Group, Inc.; <I>the highest such rating in the Company&#146;s history.</I> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Notwithstanding Cryo-Cell&#146;s significant progress since fiscal year 2003, rising industry costs in recent years associated with operating a state-of-the-art laboratory in a recently regulated environment, along with increased expenses
related to sales and marketing in an intensively competitive landscape, have contributed to the Company&#146;s predictable business challenge of balancing growth with profitability. The current Board and management team, however, has remained
steadfastly focused on building enterprise value rather than focusing attention on misguided efforts to affect the daily price of Cryo-Cell stock. <I>We believe that sustainable enterprise value creation will have the most significant and positive
impact on the Company&#146;s stock price over time.</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">As Cryo-Cell continues to execute the Company&#146;s long-term strategy, we are guided along our
journey by a collective vision of success based on our team&#146;s expansive business and technological knowledge, experience and industry-recognized expertise. We are confident that the current board and management, with the addition of Andrew
Filipowski, are best suited to build on the Company&#146;s success and to continue to add value. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In our view, the Portnoy Group has a conspicuous lack of
relevant indicated professional experience in the stem cell preservation industry; regenerative science and women&#146;s healthcare; or relevant public company operating experience. The group consists of two brothers, David and Mark Portnoy; an
accountant with prior Portnoy affiliation; a professional with experience in water heaters and home comfort systems; a cardiologist; and a professional with experience in software and hardware integration solutions, also with prior Portnoy
affiliation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Portnoy Group&#146;s overly simplistic platform to &#147;eliminate any and all unnecessary costs&#148; and &#147;maximize the return from
the deployment of CCII&#146;s marketing resources&#148; does not provide Cryo-Cell with any strategic direction or meaningful operating plan to create substantive shareholder value. We believe that Mr.&nbsp;Portnoy&#146;s rhetoric will ring hollow
in the new and complex frontier of regenerative medicine and women&#146;s healthcare that is governed by rigorous scientific, technological, regulatory and commercialization protocols. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>THE PORTNOY GROUP IS SEEKING CONTROL OF YOUR COMPANY WITHOUT PAYING </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>YOU A CONTROL PREMIUM </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Mr.&nbsp;Portnoy and his group
are seeking all six board seats that are available at the upcoming Annual Meeting. If successful, a stockholder group that owns only approximately 13% of the Company&#146;s outstanding shares of common stock will control the Company. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Currently, your Board is comprised of five experienced individuals whose common purpose is to operate the business in the best interest of all stockholders. With the
addition of Mr.&nbsp;Filipowski, who is one of the Company&#146;s single largest individual stockholders and who brings a wealth of financial and strategic vision and experience, the Company has added another independent-minded voice to the Board.
<B>The Board urges you not to hand over control of your Company to the Portnoy Group.</B> </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>VOTE THE WHITE CARD! </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">When you compare the track record, performance and qualifications of Cryo-Cell and our current Board with the inexperienced Portnoy slate and their non-specific
&#147;strategic&#148; plan, we believe you will agree the choice is clear: The Cryo-Cell nominees are the right choice! </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>We strongly recommend that you
vote FOR the Cryo-Cell nominees by signing, dating and returning the WHITE proxy card. </B><I>We urge you NOT to sign or return any gold proxy cards that may be sent to you by Mr.&nbsp;Portnoy, as that will nullify your vote on the WHITE proxy card.
</I>If you do return a gold proxy card or have already done so, you can automatically revoke it by signing, dating and returning your WHITE proxy card. If you need assistance or have any questions, please call Georgeson Inc., which is assisting
Cryo-Cell with proxy solicitation, at (888)&nbsp;605-7511. As always, we welcome your comments. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">On behalf of your Board of Directors,</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top">

<IMG SRC="g73952img002.jpg" ALT="LOGO"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Mercedes Walton</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">Chairman and Chief Executive
Officer</FONT></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">If your shares are registered in your own name, please sign, date and mail the enclosed <B>WHITE</B> Proxy
Card to Georgeson Inc. in the self-addressed, postage-paid envelope provided today. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">If your shares are held in the name of a brokerage
firm, bank nominee or other institution, please sign, date and mail the enclosed <B>WHITE</B> Voting Instruction Form in the self-addressed, postage-paid envelope provided. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Remember&#151;only your latest dated proxy or voting instruction form will determine how your shares are to be voted at the meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">If you have any questions or need assistance in voting your shares, please contact our proxy solicitor: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g73952img003.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">17 State Street, 10th Floor </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">New York, NY 10004 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Banks and Brokers (212)&nbsp;440-9800 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Stockholders Call Toll Free (888)&nbsp;605-7511 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g73952img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73952img001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!X17AI9@``24DJ``@````&`#$!`@`1
M````5@````$#!0`!````:`````,#`0`!`````LAJ`Q!1`0`!`````0```!%1
M!``!````Q`X``!)1!``!````Q`X```````!-:6-R;W-O9G0@3V9F:6-E`$2@
MA@$`C[$``/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H<
M'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T-
M&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,O_``!$(`#$`IP,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0``
M`````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%
M$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U
M-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*
MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:
MX>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#
M!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q
M$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?H
MZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/:/$7B&U\.Z?]HG^>1\B*$'!<_T
M'J:YFWL/%_B9!=7>IG2;5^8XH00V/H"#^9_"H8HQXG^)<YG&^STP$*AZ%E./
M_0LG\*]#J_A,U[WH<-)X*UNV'FV'BBZ,PZ+*6"GZG<?Y&G:+XMO[35QHGB6)
M8KDD".X``#D],XXY]1]*[>N<\6^%_P#A([>W\F9(+F!\K(PS\IZCCWP:%*^C
M&XVUB='17-S^(+C3O$>F:+<+$XFMO,FN"2,$!LGZ?+^M9T_C>]OKB6+P]H\M
M]%$=K7#9"D^P_P`32Y6/G1VM%<S8>)KA_%<FAW]M'"WE[X74GY^`<?EG\C73
M4FK#3N%%8'BGQ%)H,-HMO`MQ=74OEQQ,<9'<_F0/QJGJWC!K:^72M,LSJ&J8
MQ(L9^2,]\G_./6A1;$Y)'5T5QK:EXZ@3SI='T^5!RT43'>![?,?ZUJ:!XJL]
M<AE&UK:Z@!,T$O50.I'J*'%@I+8A\4>*TT$1VMO%]IU&?'E0C/&>`3CWZ#O6
M3%X=\5ZPHGU77I++=SY%OV'H=I`_G5;P3"=>\1:EXBNEW%7VP`\[2?\`!<#\
M:]#JF^71$I<VK.$E\)^)=-!GTKQ'//(.?*G)`;\R0?Q%:'A;Q:^J7,FEZG"+
M;5(<@KC`DQUP.Q]OQ%=77,:SX5EOO$MCK5G<)!+`5\T%3\X!]O49'TQ1>^X^
M6VL3IZ*QO$7B.S\.V:RW`,DTG$4*GYG/]![UBQZKXXO(Q<V^CV,,3#<D<['>
M1[_,/U`J5%C<DM#LZX^XU.]7XFVNG+<N+-H"S0_PD[6.?T%3Z)XO:ZU,Z1J]
MF;#41]U2<I)]/Z=<^M9US_R5^S_Z]C_Z`]4E:]Q.5TK%EM4OA\3DT[[2_P!C
M,.[R?X<["?YT54;_`)+`G_7O_P"TS12ET"/49X!X\1^(U?\`UGG?^SOG^E=_
M7G=T_P#PB?Q%-[-E=/U($,YZ*21G\F`/T->A@A@"""#R".]$][A#:PM%%<+\
M1M1\RUM=#MLO=W4JL8U_NYP!^+8_*DE=V*D[*Y2\:6;ZAX\TJS21H_/@$;,O
M4*6<-^F:]!M+6"QM8[:VB6.&-=JJHZ"N#N;,:?X_\,V:G(@LECSZX#C->A54
MMD3#=LXCQ];264NG>(K9?WMG*%DQW4G(S[9R/^!5V5M<1W=K#<PMNBE0.A]0
M1D5%J=C'J>F7-E+]R:,IGT/8_@>:XOPOKS:5X4U.VO.+G2"R[&[Y)VC_`+ZR
M/RI;H/AEZE75KUK_`,7ZCJ*_-;Z%;-Y>>AFYQ_X\3_WQ6M\.=.2'0FU-\O<W
MLC,SMUV@D8_,$_C571-#F;X=WQ8%KS48WG.1RW&5'XXS_P`"K0^'=]'=>%8K
M<-F6U=D<=QDEA^A_2JEMH3%>\FSK*Y+5?#T$_BD7L#O%/);E9`I`5P0RG/KQ
M_(5UM<9XIU25?%&D:99!&GF.)N.50L,'(]`&/]*X\5"K.FU1>OK;3KKT-X."
ME>>QI>$]/@TFTNK&#=@3&0ECGJ`./RKH:X;1M9N=*\87>BZJR+'-@VSA=H8]
MN?\`:'OU&*[FGAH584HJL[R"<H.3Y-@HHKSGQ?*/$7B[3="MB76!\SD=!G!;
M\E'ZXKH2N9RE9"27EC=_$VYGU6ZBBMK!`L`E<`;QCU]RQ_`5V/\`PE&@_P#0
M7L_^_HKC;;3=/D^)FIV.I6T<J7"F2$.."Q`;C\-WY5UO_"(>'_\`H%6_Y&KE
M;2Y$>;6QRWCW4-(OM/MKVPU"W?4+64&,Q2`MM/7\C@TL-S]M^)NDW6,>?8+)
MC_>C8_UK6UO3/"6@6:W-[I<6QW"*J)EB<$],^U9@2./XIZ8D,1BB6R`2,C!0
M>6V!^%-;":=]?(D;_DL"?]>__M,T4-_R6!/^O?\`]IFBHET+AU]3K-8T>TUS
M3WL[Q,J>58?>1O4&N3@T[QEX:'D:>\&J6*_<20X91^)!'T!(KO**2E8;BGJ<
M.^L>.;M?*M]#@MF/!E=AQ[C+8_G5WP[X0>POFU;5KG[9J;\ALY6/Z9ZGM[5U
M=%/F[!R]6<OJ>BWUSX[TO5(HU-I;Q;9'W`$'Y^W7N*ZBBBDW<:5@KS'Q9HOV
MGQY;V=M*5&I*C7"+V`/)/X+GZ@UV.O>)#H<T4?\`9MU=F52085R`<]#69X6L
M+Z^UF\\2:K;M;RS`1V\+YRB?0_0?KZU4;K4B5I>Z=='&D4:QQJ%1`%4#L!7&
MWOAK5-'U>75?#,D?[XYGLI#A6/7CM_+'8]JZ36?.^PQ^1OW_`&NVSLSG;YR;
MNG;&<^V:YO6&U:U?Q)=6_P!KEAD'D+"FXE"8%V21CV<D-CUS_#S*=BVDQS:Y
MXQF0PP^'(XICQYLDH*CWQD?SJUX;\+36%[+J^K7`NM5FZL/NQ@]A[]OIP*GU
MG28KO7]*E9+@JSN)C'-(JX",5R%('7%07D,<GBIWN#@#R?+W22CUSM"G:>?6
MGS=A<O5EWQ'X9L_$=JJRDQ7$?^JG49*^Q]1[5@0GQUHBB#R+?58%X60O\P'N
M203^.?K5S5K*]>\U&\ACE4Q3Q[)TN95=4"1EMD8&UOXNIP3G(-+XG_M.W?5[
MRR^TR1C3!&T$6XDD^=\\8'\:G;G')![D+0I=`<;NY2FO?'6K*8(-.ATU&X,S
M,-R_F2?R&:V?#'A2#P_&\SR&XOIO];.WYX'MG\Z9KO\`:LZVL.FQ2M);QBZ8
MB3RPSC[D;$]5;#[A[#UJ6^TVTU._TR]\NYVS'+XED3Y?+)7<H(QSC\:'+H"C
MK=D/BGPNVM-#?6,_V;4[;_5RYP&'4`D<CGH?K5&/6O&=M&(+CP_'<3`8\Z.4
M!6]R`?\`"M?4?MWV?6_LIF$OE+Y)098':<[,\;O3WQ2:4;?^TC_9LMQ):>0?
M/,LDC@29&W!<GYL;]W?[N>U'-T8..MT8UKX=UC7=7AU+Q,8HXK<YALHSD`^^
M"1CIW.<5<GT2^?XB6VKK$OV)(2C/O&<[6'3KW%1:"-4M+G1K&[-U+"+5I5GD
MW'@JN8Y#_>5LXSR01U(8U9TR?4O[>>[GAG%EJ#.D89B1'L'[LA?X0RJ[$GN5
M'I1S,.5$3:'?GXBKK'E+]B$6W?O&<[,=.O6BM30[Q9(Y[:21S<+=7)*N&R%\
MY]O)[8QCVQ12;N-*QKT444AA1110`4444`%%%%`!1110`4444`%%%%`!1110
/`4444`%%%%`!1110!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g73952img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73952img002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!X17AI9@``24DJ``@````&`#$!`@`1
M````5@````$#!0`!````:`````,#`0`!`````KR?`A!1`0`!`````0#]_Q%1
M!``!````Q`X``!)1!``!````Q`X```````!-:6-R;W-O9G0@3V9F:6-E`("@
MA@$`C[$``/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H<
M'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T-
M&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,O_``!$(`#8`I0,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0``
M`````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%
M$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U
M-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*
MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:
MX>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#
M!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q
M$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?H
MZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/?C32>:Y-?B%I\?FQ7^GZI9W<3,
MIMFM'=FQW4J""/?-1Z1XQ">%EUWQ#)':Q7<SO:1(A+^3_`"HR2V`2<=J`.PS
MQ3#*@D$9D42$9"%N3^%85_JTVH26NGZ),OFW4(G>ZQD00'HX'=CT4'W/:LW7
M/!VE0^'[VXACD_M*&)IX[]Y"TXD4;@V[/MTZ4`=EFEJEI5T][H]E=/P\T"2-
M]2H)_G5R@!:*2B@!>:,TE+0`C,54G!.!T'>L==;N;=$FU33FL[=\8F$HD$>>
M@DX&WZ\CWJQJ&M6>G7^GV4YD-Q?RF.%47=T&23Z`>OO5Z1$E1HY%#HX*LK#(
M(/44`/SGG/%&:QM`+6\5SI<CES82^6C$Y)B(#1Y^@.W_`(#6QQ0`M&:3--DE
MCAC:65UCC499F.`!ZDT`/I<TT$,H((((R".]+0`9YI:2B@!5HH7O10!SWC34
M18>&YU\WRGNC]G5_[@;[S?@H8_A5'1M)4:3)JM]#ME>U:.VA;_EUMMORH!V8
M@98^IQVJGX@M3XG\?:=I.2;'3(OM=YCHS,<(A^N#^&:U?'.HOI_A6Z6')NKP
MBT@`ZEY/E_09/X4`4/AII\EKX/M;NX):YNT5RQZB-1MC7Z!1G\36KXNF9?#L
M]K$?](OB+.$>K2''Z#)_"M6RM4LK"WM$'RP1+&/H`!_2O/O%GC"*QNO[5BB^
MU1V4C6NGPYXN+L\.WNJ#Y?J3B@#T2WA6UMHK>/A(D5%^@&!4M<G=>+)M,U+P
MSI=_;PK?:L"+A58XA(7/'K\W'-2Q^/O#LFH7EJMXVRSC,D]T8SY"X."H?H6S
MQ@4`=/WJEJ&K66F-;+=S;'NI1#"@!+.Y]`/U/:LB3QQH2Z):ZM'<R307;%+6
M.*)C+.P."%3J>E<ZGBBWEN=3\7WMG<0P::HL+2VG4+)YS<OWP"257/H#0!Z.
M*9)*D,;22,J1HI9F8X``ZDUR.F^/+<:'I%WK40M;W5)?+M[6#,C,"V%;'7;C
M!S5WQ,WV^XT_P^I(%_(7N"/^>$>"X_X$=J_B:`&:)_I]S<^*;[$:21E+,/QY
M5L.=Y]"WWC[8J7PCXF;Q39WEZMKY-K'=-#;L3S*@`^8CMUK#\8:S%K%JGA?1
M9<R7DZ6D]U&N8;=3DE2PX+$*1M'XXKI[2WTWPGX>2(RK!8V<>7ED/7N6/J2?
MYT`06LFSQOJ40Z-96\C#WW2#^5:M_?0:;8SWMT^R"!"[GV_QKR'6/&EW;3ZU
MJ$$BZ?<W`C13+@RI&`?*C1#_`!MN+L3PH([U>?4M8N-!\.^&);RWU#Q*]P);
ML&7>B*FYQYC#@X^4XZG;0!LV/B*]M-9NM4UZ^>"S$*1C3XXBXAE<[D3@$M)L
M&3_O`5GZ[XE/BV]BTFVTK67TJ%MU^$ML/(00=A!(.!D$^Y%;^H:GIO@+PW+'
M)=B?465I?GYDN)VZNP'09(Y/`&!6?%JUCX#\.B*YNXK[7K@!FBC;)DE<]_[J
M[FY)_P`*`-Z+QEI,;1PW4-]IVXA$^UVCQKZ`;L8'YUT?2O//#WC:ZMK>6U\4
MJLB1W9MSJUOM:U9FP0I/\.,[<XQQUKK+?Q1H%V=MOK6GR'T6Y7_&@#7R:*9'
M+'*H:-U<>JG/\J?0`Y>A^M%(O3\:*`.<\(:-=:987%UJ1!U/4)C<W.#G83T0
M'T'-+K&BW&J^)M&N7*?V=IY>=ES\SS8PG'H.371&DH`YW7KVZN;F/0-+D,=Y
M<)OGN!_RZP]"W^\>0OY]JYAO"FO7UQIUY;VVGV$6CRM'I^GW8,JLO0RR,O\`
M$>&`_/FNTT;2&TN.YDGG^TWEU,TTTY7;N_NJ!V"K@`5I4`>?:CX!O]0OX+J?
M4$FNV262XO"-I$NPK$B+_"B[F/7.>:BNO!_B37/#-IH5PVF:/:6GEE/LVZ9I
M'3OV`&<GN<UZ/BB@#B_^$-U"'6[6ZLM3MK6WALDM!MM<R1X)+&+)(7=W)R:J
MW?PQ2_LIM.N-?OCICW)NT@")N$A.26<@EN]=]2T`<?!\/=/M]8T[4$NIW-H_
MF-YV)'F<#"DN>BKDX48%;&L>&=+UZ:WEOXI&>W#*ICE9,JV,J=IY!P.*U\<T
MM`&1>^'K*ZT9=,ME^PQQ,LD#VRA3"ZG(9>V?Y\U3@\*"2ZBN=:U.ZU>6%MT2
M3A4A1AT81J,$^YS714H'4F@#+E\.:+-=W5W+I=K+<7:[)Y'C#&1<8P<^P%5[
MCPCHTNGQ6<-H+.*&3S8VLV\EE;!&0R\]"16]24`8UIX6T6SL9[1+".2.Y7;<
M&8F1YA_M,W)I8?"V@P6$UA%I-HEK-Q+&(QA\<C)ZFM@T8H`Q;_PMHVIZ9;Z9
M<6,8L+>594MHQL0E>@('4<]*E?PUH4D8B?1=.*`<#[,G'Z5JT"@#G)/`?AEC
MN32T@;.=UO(\1'_?)%(?!L"G-OK.N6X[+'?,0/\`OK-=)2T`4=&L;G3K#[-=
M:A+?LLC%9I@-^TG(!(ZD#C-%7UZ'ZT4`&*3;110`;32;#[444`&PT;3ZT44`
M+MHVFBB@`VG/:C;110`;31@T44`+@]J,<444`)BC!HHH`-M&#110`N#1@T44
)``&!1110!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g73952img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73952img003.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!X17AI9@``24DJ``@````&`#$!`@`1
M````5@````$#!0`!````:`````,#`0`!`````-MC`Q!1`0`!`````0#]_Q%1
M!``!````Q`X``!)1!``!````Q`X```````!-:6-R;W-O9G0@3V9F:6-E`("@
MA@$`C[$``/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H<
M'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T-
M&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,O_``!$(`"4`CP,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0``
M`````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%
M$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U
M-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*
MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:
MX>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#
M!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q
M$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?H
MZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`.X7Q4WC/XA3^&-+N)(=*TM&?4YX
MF*O/(&VB%6'(7/4CDX(X[]DWA[1BA4:9:H<8WI&%<>X8<@^^<UXG^SMYHU_Q
M4+O/VO$?F;NN[>^[]:]XNKN"SC#SL54G`PI;G\!0!A^$-)OM%AU6TO;VZO5-
M^\EO/=2&1S$40J,GKCD?A71UCV'BK0M5NY;6PU*&XGA;9*D>28VYX;CY>AZ^
ME<7X2\9P^-=2UF^O+Y[;2K6X^RV-M&[1[P!DRN5Y).1@9P/UH`],HKS3P]XU
MO-.U7Q99:N+JXTC24:[L[^6,Y>(<F/<0`Y!(`/4\YK4\!WMYXR\-)XBU6:9#
M>R2&WMH)6C2"-6*J/E(+-P22?7M0!V]%<!H'B>XE\<ZYX%U2>226U5;BSNU;
M9))"0IVL1_$NX#/<9S[X7P^U#Q#XGL_%L%UJEU*ME>S0VG[[RW+8(52XY`&!
M]<^U`'KE%>2R:KXOTNW\$>&->NRE]JEU(E]>0N-YC0Y5`XZ,P(!(Y]\UI?$&
M:3PS+X?;3)+I8=0U%+"[M8YW_?1OW!SE6&/O+@\T`>D45Y1-K$GASQ1HWP\M
MM:O)(R)+N^U&ZDWS+%\S+$K=LXQGJ`1C%7=?\1W7A_Q=X>.B/=ZAIE]*UOJ%
MN`\PB!*A903DJ1N.><$#\:`/2J*\]E\;Z,/'6KZ%XAU-M-:V:);)'F:&.1&0
M,7W@C+;B1R>@&.]6M;\1R>`?`%[JUY>G5G69A9.[@F4.W[M6(`S@=2.H6@#N
M**YO1-,NK_PW9W6HZC=MJ5U;K+)-#*4$;,N<(@^7`S@9!SCG-<GHWC2\\1^"
M/$T=U.]OKOA]9XY9;9C&)&56V28]RIR.F10!ZA2CK7G_`,,;G4_$_@#3=1UJ
M^N9'<.H*R%&DP[#<Q7!]@/0>]6/AYJ]]>7WB?2;VZENUTK5'@MYIB"_E$9"L
M>^,'D\\T`53X5/A#Q_-XITFV>73M21H]4MXAN>-RVX3*O5AGJ!R,D@&NKN?$
MVDVMJ9_M8F./EA@!DE<^BH.2:UJ,#.<<^M`'EWPH\.:[I>K^*M1US36LEUB=
M+F*-I%8X+2$J<$X(W#KZT?#339/A]<ZWX<U8-#!)>&YL;MQ^ZGC(`QNZ!AM&
M5///&:]1HH`P=4@A\6:/J>D+G[#<VK0FZ&>78$?+Z@=<].WK6!\."_A;PA#X
M>UW;9WNG221Y<X29"Y971NC`@X]01R!7>T4`>:^'M!EF^)FO>/;]'MK%XUM;
M%9%(:1`%4RE>H!V\9Z@YJG\'%DL9?$T-W#-;R76KR2P"6)D\Q/[PR.17JU9/
MB?6#X?\`"VJ:NL?FM9VSS*AZ,P'`/MG%`'!>/?&/A[3?&":3XMCN4L8+>*\L
M9(%)/G;F!?<OS*5P,8XZY[4W2?B/\.=6U^R:75;F:_B)2TEU&-@L3-P=IQM4
MGIN//O6'X=\/OXC\3?9M2N#--NDGN[AL%Y&CV*Y7T):0JO9$7C#/FNT\;>$]
M`M_A[J&FV6B6:2RQ>39QQ0J',['"8/4G=@D^@.>]`&?XBT*ZT7XNZ5XV2&2?
M3)(#:7QB4NUN=I"R$#G;R,D=,&N[.LV\[Q1:>Z7<KLN?+.51<\LQ'3C./4X%
M6K""2UTZUMY7WR10HC/_`'B``35B@#@=2M/#7BZZU&P\6Z+'%-:3O%;W,\31
M>;%U#1R\9ZD$`]1TYKC+#X:7VJ?#WQ/H5K/.+!M0\_0Q=DC*IWYZ*V2`<#^]
MCFO<:*`.9T#7[:#PO8C4=]I>V]LD<]I(I\U9%4`@*.6R1QC.>,5P_A_PO=>'
M_!'C'5-4B>'4_$*W$J6@4L\8*N40@9^8ESQ]!7KU%`'`_"-Q8_#+3+6[62"X
MMHY&FBEC960&1R,@CTYJM\.6,/BSQF98Y8Q>:H9;8O$RB5-I^921R*]'I1UH
M`,48HHH`,48HHH`,48HHH`,5#>6<%_93V=U&LMO/&T4L;=&5A@C\J**`."M_
MA<]G?I/;:_*JQ$>6S0$RC`"C+AP"=H52=H)`&<XKL[/25MY$GN;F:\N4!"2S
EX^3/7:``!GUZ^]%%`&ABC%%%`!BC%%%`!BC%%%`!BC%%%`'_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
